Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 22, 2007, Pages 6151-6154

  Urbahns, Klaus ^a   Härter, Michael ^a   Albers, Markus ^b   Schmidt, Delf ^a   Stelte Ludwig, Beatrix ^a   Brüggemeier, Ulf ^a   Vaupel, Andrea ^a   Keldenich, Jörg ^a   Lustig, Klemens ^a   Tsujishita, Hideki ^c   Gerdes, Christoph ^a  

^a BAYER PHARMA AG   (Germany)

^b BAYER AG   (Germany)

^c Research Center   (Japan)

Author keywords

V 3; Arginine; Biphenyl; Guanidine mimetic; Restenosis; RGD; Smooth muscle cell; Squaric acid amide; Urea; Vitronectin

Indexed keywords

BIPHENYL DERIVATIVE; RECEPTOR BLOCKING AGENT; SQUARIC ACID DERIVATIVE; VITRONECTIN RECEPTOR;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INDICATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RESTENOSIS; STRUCTURE ACTIVITY RELATION;

BINDING SITES; BIPHENYL COMPOUNDS; CYCLOBUTANES; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, VITRONECTIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 35148882994     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.039     Document Type: Article

References (25)

1. Samanen J., Jonak Z., Rieman D., and Yue T.L. Curr. Pharm. Design 3 (1997) 545
2. Miller W.H., Keenan R.M., Willette R.N., and Lark M.W. Drug Discov. Today 5 (2000) 397
3. Duggan M.E., and Hutchinson J.H. Expert. Opin. Ther. Pat. 10 (2000) 1367
4. Mousa S.A. Med. Res. Rev. 23 (2003) 190
5. Hoelzemann G. Idrugs 40 (2001) 72
6. Nagarajan S.R., Lu H.-F., Gasiecki A.F., Khanna I.K., Parikh M.D., Desai B.N., Rogers T.E., Clare M., Chen B.B., Russell M.A., Keene J.L., Duffin T., Engleman V.W., Finn M.B., Freeman S.K., Klover J.A., Nickols G.A., Nickols M.A., Shannon K.E., Steininger C.A., Westlin W.F., Westlin M.M., and Williams M.L. Bioorg. Med. Chem. 15 (2007) 3390
7. Urman S., Gaus K., Yang Y., Strijowski U., Sewald N., De Pol S., and Reiser O. Angew. Chem. Int. Ed. 46 (2007) 3976
8. Heckmann D., Meyer A., Marinelli L., Zahn G., Stragies R., and Kessler H. Angew. Chem. Int. Ed. 46 (2007) 3571
9. Urbahns K., Haerter M., Albers M., Schmidt D., Stelte-Ludwig B., Brueggemeier U., Vaupel A., and Gerdes C. Bioorg. Med. Chem. Lett. 12 (2002) 205
10. The B-series analogs of 5 and 6 are examples 25 and 26 (Table 3).
11. Urbahns K., Haerter A., Vaupel M., Albers M., Schmidt D., Stelte-Ludwig B., Brueggemeier U., Gerdes C., and Tsujishita H. Bioorg. Med. Chem. Lett. 13 (2003) 1071
12. For details of the syntheses and the primary assay procedures see: Urbahns, K.; Haerter, M.; Albers, M.; Vaupel, A.; Schmidt, D.; Stelte-Ludwig, B.; Gerdes, C.; Lustig, K. WO 0035864, 2000; Chem. Abstr. 2000, 133, 43809.
13. Amato J.S., Karady S., Reamer R.A., Schlegel H.B., Springer J.P., and Weinstock L.M. J. Am. Chem. Soc. (1982) 1375
14. Use of imidazolines. Batt D.G., Petraitis J.J., Houghton G.C., Modi D.P., Cain G.A., Corjay M.H., Mousa S.A., Bouchard P.J., Forsythe M.S., Harlow P.P., Barbera F.A., Spitz S.M., Wexler R.R., and Jadhav P.K. J. Med. Chem. 43 (2000) 41
15. Pitts W.J., Wityak J., Smallheer J.M., Tobin A.E., Jetter J.W., Buynitsky J.S., Harlow P.P., Solomon K.A., Corjay M.H., Mousa S.A., Wexler R.R., and Jadhav P.K. J. Med. Chem. 43 (2000) 27
16. Squaric acid amides have been used as α4 integrin inhibitors before: Head, J. C.; Porter, J. R.; McKay, C.; WO 2002-010136.
17. Chem. Abstr. 2002, 136, 167287 and WO 2002-042264.
18. Chem. Abstr. 2002, 136, 401746 (Celltech).
19. 3 as described: Kumar, C. S.; James, I. E.; Wong, A.; Mwang, V.; Field, J. A.; Nuthulaganti, P.; Conner, J. R.; Eichman, C.; Ali, F.; Hwang, S. M.; Rieman, D. J.; Drake, F. H.; Gowen, M. J. Biol. Chem. 1997, 272, 16390.
20. The binding constant to human serum albumin (HSA) was determined by equilibrium dialysis. Loidl-Stahlhofen A., Schmitt J., Noller J., Hartmann T., Brodowsky H., Schmitt W., and Keldenich J. Adv. Mater. 13 (2001) 1829
21. Sebille B., Zini R., Madjar C.V., Thuaud N., and Tillement J.P. J. Chromatogr. 51 (1990) 531
22. Membrane affinities were determined as described. Briefly, the reduction of compound concentration after incubation with liposomal egg yolk lecithin followed by ultracentrifugation was measured by HPLC:. Loidl-Stahlhofen A., Hartmann T., Schottner M., Rohring C., Brodowsky H., Schmitt J., and Keldenich J. Pharm. Res. 18 (2001) 1782
23. The prediction of hepatic clearance was performed according to. Houston J.B., and Carlile D.J. Drug Metab. Rev. 29 (1997) 891
24. Briefly, compounds were incubated (1 μM, 37 °C) with 0.2 mg/ml rat microsomal protein. Samples were taken at 7 time points within 30 min to calculate half-lives and extrapolate clearance. Compound A showed an extrapolated clearance of 0.6 l/h/kg in this in vitro assay.
25. Recent review on arginine mimetics. Masic L.P. Curr. Med. Chem. 13 (2006) 3627